In China, internet medical institutions and digital health/digital therapeutics start-ups are also facing the same development bottlenecks and the awkward situation of being unable to expand their markets. It is worth considering whether they can draw on the experience of the ATA-DTA merger to create a collaborative platform for internet hospitals/telemedicine, digital health, and digital therapeutics technologies, and jointly promote the widespread application of AI-driven digital technologies.

Online Lecture: This Sunday, from 8:00 pm to 9:00 pm, we will invite two senior vice presidents from ATA and DTA to share their insights on the cooperation model between ATA and DTA. They will also discuss how to incorporate digital therapeutics solutions into the internet hospital/telemedicine service system, as well as the profit models and service items involved. To participate in the online lecture on Sunday, please register via WeChat: GlobalMD2020.

After the merger of the Digital Therapeutics Alliance (DTA) and the American Telemedicine Association (ATA), a new action plan has been proposed, along with a vision for building AI-driven digital medical technologies. On April 13th (Sunday at 8:00 pm), we will invite two senior executives (Sr. VP) from Digital Health Action to participate in an online discussion. They will share the milestone significance of the integrated and expanded application scenarios of internet telemedicine and digital therapeutics. They will also discuss how to promote AI-driven digital health technologies, digital therapeutics, and telemedicine service projects.

ATA-DTA, in collaboration with the Global Doctors Organization, is jointly hosting the [Study Tour to the US for the Digital Therapeutics and Internet Telemedicine Industry Annual Conference NEXUS]. We sincerely invite executives from domestic digital health/digital therapeutics and wearable device companies, medical experts, heads of internet hospitals/telemedicine service institutions, and supervisors of internet hospitals to participate in the 2025 NEXUS annual conference. The itinerary includes pre-conference visits to the Digital Health Center of Stanford University and the AI Smart Hospital project planning at the headquarters of NVIDIA. The schedule is as follows (time, location, and content):

May 1st: Depart and arrive in San Francisco (Marriott Hotel)
May 2nd: Visit the Digital Health Center of Stanford University, focusing on the R&D and design of AI digital health and wearable products, verification of the safety and effectiveness of DTx, and testing of AI algorithms.
May 2nd: Visit the NVIDIA Smart Hospital project and analyze the latest application cases of AI in medicine.
May 3rd - 6th: Participate in the 2025 NEXUS-ATA-DTx Digital Therapeutics and Telemedicine Annual Conference (Brief introductions of the enterprises for communication are as follows).
May 7th: The annual conference ends, and participants can make their own arrangements or return to China.
*The final itinerary is subject to the arrangements of the host party.

During the NEXUS annual conference (May 3rd - 6th), there will be discussions with enterprises on DTx technology cooperation and the introduction of products to the domestic market. For detailed information about the enterprises, please contact via WeChat: GlobalMD2020. The digital therapeutics enterprises include:

01 JOGO Health: An FDA-recognized digital therapeutics solution for stroke rehabilitation. It is an AI-driven digital therapeutics combined with wearable devices for stroke rehabilitation (already in the Chinese market, including Peking Union Medical College Hospital, Affiliated Hospital of Northwest University Medical School, Guangdong Provincial Hospital, etc.).
02 Dario Health: An FDA-approved digital health solution for cardiometabolic conditions. It is a digital health platform (a listed company) offering cardiometabolic digital health solutions, including diabetes, hypertension, and weight management/weight loss in a virtual center model, with experience in a membership-based business model.
03 Cognito Therapeutics: An FDA-approved digital therapeutics company for the best DTx treatment of dementia. It develops the best digital therapeutics for early neurodegenerative diseases (dementia and Parkinson's disease) - AI-driven DTx and wearable devices.
04 Cognoa: An FDA-approved digital therapeutics solution for childhood autism. Its Canvas Dx is the first digital therapy for childhood autism and currently the only FDA-authorized digital auxiliary diagnosis solution, helping doctors diagnose or identify autism in children aged 1.5 to 6 years within a few days (instead of months or years).
05 MedRhythms: A leading global digital therapeutics company. It uses smart sensors, music, and digital software apps to build evidence-based neurofeedback interventions, aiming to improve walking movement rehabilitation.
06 Nox Health-DTx: A DTx solution for chronic sleep disorders. It changes the quality of life of patients by improving sleep quality. Their digital therapeutics software combines data, science, AI, and empathy, and it is the first FDA-approved DTx for the treatment of chronic insomnia.